Mobile

A 24-Week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Glimepiride (a Sulphonylur...

Update Il y a 4 ans
Reference: EUCTR2007-005931-27

A 24-Week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Glimepiride (a Sulphonylurea) in Subjects with Type 2 Diabetes who Have Inadequate Glycaemic Control on Glimepiride Therapy Alone

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the efficacy of dapagliflozin compared to placebo as add-on therapy to glimepiride in improving glycaemic control in subjects with type 2 diabetes, as determined by the change in A1C levels from baseline to Week 24.

Inclusion criteria

  • Type 2 diabetes mellitus

Links